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Abstract: 
Schizophrenia is a severe mental disorder that affects 0.5–1% of the population worldwide. 
Current diagnostic methods are based on psychiatric interviews, which are subjective in nature. 
The lack of disease biomarkers to support objective laboratory tests has been a long-standing 
bottleneck in the clinical diagnosis and evaluation of schizophrenia. Here we report a global 
metabolic profiling study involving 112 schizophrenic patients and 110 healthy subjects, who 
were divided into a training set and a test set, designed to identify metabolite markers. A panel of 
serum markers consisting of glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine 
was identified as an effective diagnostic tool, achieving an area under the receiver operating 
characteristic curve (AUC) of 0.945 in the training samples (62 patients and 62 controls) and 
0.895 in the test samples (50 patients and 48 controls). Furthermore, a composite panel by the 
addition of urine β-hydroxybutyrate to the serum panel achieved a more satisfactory accuracy, 
which reached an AUC of 1 in both the training set and the test set. Multiple fatty acids and 
ketone bodies were found significantly (P<0.01) elevated in both the serum and urine of patients, 
suggesting an upregulated fatty acid catabolism, presumably resulting from an insufficiency of 
glucose supply in the brains of schizophrenia patients. 
 
Article: 
INTRODUCTION 
Schizophrenia is a severe mental disorder affecting approximately 0.5–1% of the population 
worldwide.1 As one of the most expensive medical illness, schizophrenia represents a serious 
burden on the health-care system.2 Clinically, it has heterogeneous presentations, with positive 
and negative symptoms at different levels of prominence across time and across individuals.3 
The current diagnosis of schizophrenia remains subjective due to its complex spectrum of 
symptoms, and the mechanism underlying the disease process has yet to be elucidated. 
 
Recent clinical studies suggest that early intervention mitigates progression and improves 
therapeutic outcomes in the disease.4, 5, 6 Establishment of biomarkers will enable early disease 
prevention, and thus improve prognosis. A niacin test proposed to measure reduced membrane 
arachidonic acid levels was suggested for the diagnosis of schizophrenia in 1980,7 but has not 
found its way into clinical use so far owing to its low sensitivity and specificity.8, 9, 10 Imaging 
modalities including functional magnetic resonance imaging, positron emission tomography and 
single-photon emission computerized tomography (SPECT), although frequently used in the 
pathological study of schizophrenia,11 have not been able to offer a diagnostic solution with a 
high enough sensitivity and specificity. Recently, genetic variants at the major histocompatibility 
complex locus have been found significantly associated with this disease from several major 
genome-wide association studies,12, 13, 14 suggesting an immune component in its pathogenesis. 
However, genetic research strategies, including linkage, association and genome-wide 
association studies, have yet to generate applicable genetic biomarkers for schizophrenia. 
 
Global profiling strategies, such as unbiased proteomics or metabolomics with body fluids, 
including plasma/serum, urine or cerebrospinal uid (CSF), may hold a significant potential for 
translating discriminating molecules into clinical biomarkers.15, 16, 17 Metabonomics, defined as 
the quantitative measurement of the metabolite composition in a given biological compartment,18 
probes significant biochemical alterations and provides mechanistic insights into the 
pathophysiology of diseases.19, 20, 21 In fact, metabonomic strategies have been widely used to 
characterize the human metabolic status in the field of central nervous system disorders, such as 
motor neuron diseases, Parkinson's disease, Huntington's disease, multiple sclerosis, 
schizophrenia and meningitis (for reviews see refs. 17, 22). Psychiatric disorders have been 
found to be associated with metabolic pathway disturbances,17, 23 which could well be reflected 
in metabonomic profiles. In 2004, metabonomic profiling of post-mortem brain tissues by the 
nuclear magnetic resonance (NMR) was used as supplement to genomics and proteomics, 
providing evidence for mitochondria dysfunction hypothesis of schizophrenia.24 It was 
repeatedly reported that schizophrenia patients showed decreased levels of various 
polyunsaturated fatty acids and increased phospholipid breakdown in both central and peripheral 
tissue. As membrane phospholipid was proposed as the biochemical basis of neurodevelopment 
hypothesis of schizophrenia,25 lipid metabolism was the focus of early metabonomic research. 
Bahn's group further reported significant alternations in levels of free fatty acids and 
phosphatidylcholine in gray and white matter of schizophrenia using ultra-performance liquid 
chromatography-mass spectrometry.26 It deserves to be mentioned that these findings are best 
viewed as hypotheses generating rather than as definitive conclusions. 
 
As brain tissues are rare and limited, CSF is an alternative as reflection of brain metabolic status, 
which can provide valuable biological specimens for the detection of altered biological 
molecules directly associated with neuropsychiatric disorders.27 Holmes et al.5 found an 
abnormal CSF biochemical profile in patients with schizophrenia as compared with normal 
controls, characterized by significantly altered levels of glucose, acetate, alanine and glutamine. 
They further found that these alterations in CSF of schizophrenia can be traced in initial 
prodromal state of psychosis, but not sufficient to predict clinical outcome.28 However, CSF is 
only clinically accessible by means of a sophisticated procedure involving lumbar puncture; thus, 
peripheral blood samples are also considered for metabonomic study. Tsang et al.29 analyzed the 
NMR spectra of plasma from a cohort of 21 pairs of monozygotic twins discordant for 
schizophrenia and 8 pairs of matched control twins. Resonances from very-low-density 
lipoproteins, low-density lipoproteins and aromatic groups were found predominantly 
responsible for the differentiation of affected and unaffected twins from the normal controls. 
However, the affected twins were on antipsychotic medication and it is not clear whether and 
how much the drugs contributed to the alterations in lipid profiles if any. Given the key role 
lipids play in metabolism, Kaddurah-Daouk et al.30 used a targeted lipidomics platform to map 
the global plasma lipid profile of patients with schizophrenia. In their study, 
phosphatidylethanolamine and phosphatidylcholine were found decreased in schizophrenia 
patients at baseline compared with healthy controls, which supported the membrane 
phospholipid hypothesis. Thereafter, the plasma tryptophan and purine metabolites were 
investigated in schizophrenia by Yao's group using the metabolomics platform of high-pressure 
liquid chromatography coupled with electrochemical coulometric array detection. N-
acetylserotonin was found increased in schizophrenia patients compared with healthy controls, 
and some metabolite interactions within the plasma tryptophan pathway were proposed to be 
altered and implicated in the pathogenesis of schizophrenia.31 After identification of purine 
metabolites in the plasma, homeostatic imbalance of purine catabolism was found in 
schizophrenia patients,32 which is consistent with the notion of free radical-mediated 
neurotoxicity in schizophrenia. In addition, guanine was found to discriminate schizophrenia 
patients from healthy controls with a moderate sensitivity of 0.68 and specificity of 0.67. 
 
These studies exemplify metabonomic applications in schizophrenia research, providing valuable 
clues to understanding the mechanism of the condition. However, fewer of them were designed 
for the purpose of disease diagnosis. The lack of disease biomarkers to support objective 
laboratory tests still constitutes a bottleneck in the clinical diagnosis and evaluation of 
schizophrenia. To date, there has not been a comprehensive global evaluation of small-molecule 
metabolites using gas chromatograph time-of-flight mass spectrometer (GC-TOFMS) in the 
context of schizophrenia. This approach has comparative advantages in outstanding sensitivity as 
well as capability to identify metabolites over other analytical platforms. In this study, we 
enrolled a cohort of 112 schizophrenia patients and 110 normal healthy subjects as controls, 
utilizing a GC-TOFMS platform to explore potential diagnostic serum biomarkers. Urine 
samples were also analyzed using GC-TOFMS and 1H-NMR to identify additional metabolite 
markers for schizophrenia. 
 
MATERIALS AND METHODS 
Subjects 
We recruited 112 patients diagnosed as schizophrenic according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition criteria in Anhui Province, China. Of these, 64 
patients were on first-onset psychosis and 48 hospitalized for relapse after at least 1 month 
without any antipsychotic drugs. In all, 50 of the 112 patients withdrew from this project after 
enrolling. Serum and urine samples were collected from the patients at baseline before initiation 
of antipsychotic treatment. We excluded those patients who received any form of mood-
stabilizing drugs in the recent 2 weeks before clinical samples were collected. Serum and urine 
samples were also collected from 110 normal controls in the same district. We excluded 
participants with metabolism disorders (such as type I or type II diabetes) and/or with heavy 
consumption of alcohol in both patients and controls. 
 
The enrolled subjects were separated into a training set and a test set (Table 1). The training set 
included 62 patients whose serum were available after 4 weeks of antipsychotic treatment and 62 
sex- and age-matched controls; the remaining patients and controls made up the test set. All 
samples were collected following the guidelines of the local ethics committee. Written informed 
consent was obtained from all participants. The overall sampling was finished within 1 year. 
 
Table 1: Demographic details of patients involved in GC-TOF analysis. 
Group N Male % Age Height (cm) Weight (kg) BMI (kgm-2) N Smoker (cigarettes) 
Training seta        
Control 62 40.3 36.9±9.3 164.9±6.8 60.8±8.6 22.0±4.8 15 (6±3) 
SZ-BL 62 40.3 36.9±11.9 161.9±7.9 56.3±8.7 21.5±2.6 12 (16±8) 
        
Test set        
Control 48 0 28.3±8.6 160.1±4.6 53.2±6.1 20.7±2.0 0 
SZ-BL 50 42 36.9±12.6 161.2±6.2 57.0±7.9 21.8±2.3 6 (16±7) 
Abbreviations: BMI, body mass index; GC-TOF, gas chromatograph time of flight; SZ-BL, schizophrenia patients at baseline. 
a Training set consisted of patients and controls matched for gender, age, height, weight and BMI. These factors were not considered in the test 
set. Smoking habit is noted with the number of smokers (N smoker) and daily consumption of cigarettes (within the parenthesis, average±s.d.). 
 
 
Biofluid specimen preparation 
Venous blood and urine specimens were collected in polypropylene tubes in the early morning 
after overnight fasting. The fresh blood samples were placed at room temperature and clotted 
naturally after approximately 1 h. Serum were then obtained after centrifugation at 10 000 r.p.m. 
for 10 min. Serum and urine were stored at −80 °C. 
 
GC-TOF spectral acquisition and data analysis 
Serum and urine metabolites were analyzed using chemical derivatization following our 
previously published procedures with minor modifications.33 A 100 μl aliquot of serum sample 
was vortexed after being spiked with two internal standard solutions (10 μl of L-2-
chlorophenylalanine in water, 0.3 mg ml−1; 10 μl of heptadecanoic acid in methanol, 1 mg ml−1). 
The mixed solution was extracted with 300 μl of methanol/chloroform (3:1) and vortexed for 
30 s. After storing for 10 min at −20 °C, the samples were centrifuged at 12 000 g for 10 min. A 
measure of 300 μl of the supernatant was transferred to a glass sampling vial and vacuum-dried 
at room temperature; 50 μl urine sample was extracted after being centrifuged at 12 000 g for 
10 min, followed by the addition of 30 U urease. Urea was degraded for 15 min at 37 °C. After 
the addition of two internal standard solutions as in urine, the mixture was extracted with 170 μl 
methanol. The samples were then centrifuged at 12 000 g for 5 min. A measure of 200 μl of the 
supernatant was transferred to a glass sample vial and vacuum-dried at room temperature. The 
serum and urine residues were derivatized using a two-step procedure, that is, 80 μl of 
methoxyamine (15 mg ml−1 in pyridine) was added to the vial and kept at 30 °C for 90 min, and 
then 80 μl of BSTFA (N,O-bis(trimethylsilyl) trifluoroacetamide) (1% TMCS 
(trimethylchlorosilane)) was added and heated to 70 °C for 60 min. A measure of 1 μl aliquot of 
the derivatized solution was injected in splitless mode into an Agilent 6890N gas chromatograph 
coupled with a Pegasus HT TOFMS (Leco Corporation, St Joseph, MI, USA). Electron impact 
ionization (70 eV) at full scan mode (m/z 30–600) was used, with an acquisition rate of 20 
spectra per s in the TOFMS setting. 
 
The MS files acquired from GC-TOFMS analysis were exported in NetCDF format using the 
ChromaTOF software (v.3.30; Leco Co., Oakland, CA, USA). CDF (channel definition format) 
files were extracted using custom scripts (revised Matlab toolbox hierarchical multivariate curve 
resolution, developed by Par Jonsson et al.34, 35) using MATLAB 7.0 (The MathWorks Inc., 
Natick, MA, USA) for data pretreatment procedures such as baseline correction, denoizing, 
smoothing, alignment, time-window splitting and multivariate curve resolution (based on a 
multivariate curve resolution algorithm). The resulting three-dimensional data set included 
sample information, peak retention time and peak intensities. Then, the internal standards and 
any other known artificial peaks, such as peaks caused by noise, column bleed and BSTFA 
derivatization procedure, were removed from the data set. For multivariate statistical analysis, 
the resulting data were mean centered and unit variance scaled during chemometric data analysis 
using the SIMCA-P 11.5 software package (Umetrics, Umeå, Sweden). Principal component 
analysis, partial least squares-discrimination analysis and orthogonal projection to latent 
structures (OPLS) were carried out for group discrimination. The following statistics, based on 
the models, are discussed in detail throughout this article. R2X is the cumulative modeled 
variation in the X matrix; R2Y is the cumulative modeled variation in the Y matrix; and Q2 is the 
cumulative predicted variation in the Y variable or matrix, based on sevenfold cross-validation. 
The range of these parameters is 0–1, where 1 indicates a perfect fit. Random permutation of the 
Y observations, while keeping the X matrix intact, was used as a measurement of data 
overfitting.36 The default seven-round cross-validation in the SIMCA-P software package was 
applied with one-seventh of the samples being excluded from the mathematical model in each 
round, in order to guard against overfitting. A completely separate external test set was used as a 
prediction set to assess the accuracy of the OPLS model. Based on the variable importance on a 
projection (VIP) with a threshold of 1.5 from an appropriate sevenfold cross-validated OPLS 
model, a number of variables were obtained responsible for the difference in the metabolic 
profiles between different groups. These variables were also validated at the univariate level 
using the non-parametric Wilcoxon–Mann–Whitney test with the critical P-value set at 0.05. A 
false discovery rate (FDR)37 control was implemented to correct for multiple comparisons. The 
q-value in the FDR control was defined as the FDR analog of the P-value. The q-value of an 
individual hypothesis test is the minimum FDR at which the test may be called significant. In 
this study, the q-value was set at 0.2. 
 
In addition, compound identification was performed by comparing the mass fragments with 
NIST 05 Standard mass spectral databases in the NIST MS search 2.0 (NIST, Gaithersburg, MD, 
USA) software. This revealed a similarity of more than 70%, which was then verified by 
available reference compounds. Logistic regression was fitted to find a classifier composite of 
differential metabolites between schizophrenic patients and normal controls. Areas under the 
receiver operating characteristic (ROC) curve (AUC) were calculated to evaluate the 
performance of this classifier. Non-parametric Wilcoxon–Mann–Whitney test, FDR control, 
logistic regression and ROC curves were carried out on the freely available software R 
(http://www.r-project.org) with corresponding packages. 
 
NMR spectra of urine and data analysis 
An aliquot of 600 μl urine was thawed at room temperature. After centrifugation at 12 000 g for 
5 min, 470 μl supernatant urine was mixed with 60 μl D2O from Merck (Darmstadt, Germany) 
5 μl trisodium phosphate (0.4 mM) and 115 μl phosphate buffer (0.3 M, pH 7.4). The pH of the 
mixtures was adjusted to pH 7–7.4 with NaOH (1 M) or HCl (1 M) and then centrifuged again at 
12 000 g for 5 min. A measure of 600 μl of the supernatant was pipetted into a 5-mm NMR tube 
(Bruker Biospin, Karlsruhe, Germany). 
 
All samples were run on a 400 MHz Bruker Avance β spectrometer. 1H-NMR spectra were 
acquired using standard 1D water presaturation pulse sequence of the form d1−π/2−acq., where 
π/2 represents a 90° hard pulse and d1 is a relaxation delay (5 s). The resonance of H2O 
(δ≈4.7 p.p.m.) was selectively irradiated with a continuous-wave low-power pulse during d1. For 
each sample, 32 transients were collected into 16K data points, with a spectral width of 12 p.p.m. 
Before Fourier transformation, the free-induction decay was multiplied by an exponential 
function corresponding to a line-broadening factor of 0.3 Hz in the frequency domain. All spectra 
were phase and baseline corrected and referenced to TSP (δ=0 p.p.m.) manually on TOPSPIN 
2.1. 
 
Regions from δ=0–0.6 p.p.m. (TSP) to δ=4.5–6.7 p.p.m. (water and urea) were excluded before 
analysis. Using AMIX 3.8.6, each NMR spectrum was reduced to integrated segments with a 
width of 0.04 p.p.m., giving a total of 181 integrated regions per spectrum. The spectrometric 
data were then converted into Microsoft Excel format. Univariate and multivariate statistical 
analysis were conducted as described above in the section of ‘GC-TOF spectral acquisition and 
data analysis’. 
 
RESULTS 
Metabolic profiles of schizophrenia patients 
Serum metabolic profile. After excluding internal standards, a total of 330 individual peaks 
were consistently detected in about 90% of the serum samples, which are used in the next 
analysis. For the training set, principal component analysis scores plot revealed little clustering 
trends between patients and controls, while partial least squares-discrimination analysis scores 
plot using three components showed difference between schizophrenia patients at baseline (SZ-
BL) and normal controls (R2Y=0.842, Q2=0.578). With Q2 intercepting the Y axis at −0.214 in the 
999 random permutations test, the supervised model was considered well guarded against 
overfitting (Supplementary Figure 1). To specify metabolic variations relevant to schizophrenia, 
a cross-validated OPLS model was constructed with satisfactory predictive ability using one 
predictive component and one orthogonal component in the training set (R2Y=0.716, Q2=0.472). 
 
Given the success of the OPLS model in classifying patients and controls (Figure 1a), a total of 
39 paired retention time mass to charge ratio (RT-m/z) variables stood out relative to the VIP 
threshold (VIP>1.5). In all, 22 differential metabolites were annotated using the available library, 
among which 20 metabolites being validated using reference standards (Table 2). In the 22 
metabolites contributing most to the discrimination of schizophrenia patients from normal 
controls, five middle- and long-chain fatty acids (tetradecanoic acid, hexadecanoic acid, 
octadecanoic acid, oleic acid and eicosenoic acid) were found significantly elevated in patients. 
β-Hydroxybutyrate, a by-product of fatty acid metabolism, was found elevated with a fold 
change of 2.6. Cystine, a conjugation of two cysteines, was decreased in patients compared with 
normal controls. Amino acids, including glutamate, aspartate, serine and phenylalanine, were 
increased in patients compared with normal controls. 
 
 
 
 
 
Figure 1: 
 
Serum biomarker panel for schizophrenia. (a) The orthogonal projection to latent structures (OPLS) model was fitted to discriminate the 
schizophrenia patients at baseline (SZ-BL) and normal controls. (b) In all, 22 metabolites were identified with variable importance on a 
projection (VIP)>1.5. (c) Logistic regression models were fitted with different numbers of metabolites. Akaike information criterion (AIC) of 
each model was shown here. The model built with five metabolites (glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine, upper 
part of b) had the highest predictive power. (d) Receiver operating characteristic (ROC) curves were drawn for the training and test sets. The area 
under the curve was 0.945 (95% confidence interval: 0.900–0.91) in the training set and 0.895 (95% confidence interval: 0.829–0.961) in the test 
set, indicating a ‘good’ clinical diagnosis efficiency for this set of biomarker metabolites. 
 
 
Urine metabolic profile. In the training set (Table 1), urine samples were available from 51 SZ-
BL and matched controls. A total of 345 variables were used for statistical analysis using the 
same protocols as in the serum profile analysis. The cross-validated OPLS model was 
constructed using one predictive component and two orthogonal component (R2Y=0.578, 
Q2=0.352), achieving a distinct separation between the metabolite profiles of the two groups 
(Figure 2a). Metabolites contributing most to the discrimination were screened with a VIP cutoff 
of 1.5. Short- and middle-chain fatty acids were found elevated in SZ-BL urines (Table 3). β-
Hydroxybutyrate was found increased in SZ-BL urine compared with normal controls, which is 
consistent to that in SZ-BL serum. Cystine was found elevated in SZ-BL urine, which presents 
an opposite trend with that in SZ-BL serum. 
 
 
 
 
 
 
Table 2: Differential serum metabolites between schizophrenia patients and normal controls. 
Pathway Compound VIPa P-valueb FDRc FCd 
Fatty acids metabolism Glyceratee 3.10 7.90E-10 6.06E-04 2.57 
 Tetradecanoic acide 2.77 2.90E06 6.06E-03 1.45 
 Hexadecanoic acide 2.61 4.10E-04 1.76E02 1.40 
 Linoleatee 1.63 3.67E02 3.88E02 1.18 
 Oleic acide 3.01 1.36E-05 1.09E-02 2.09 
 Octadecanoic acide 1.78 7.39E-03 2.55E-02 1.14 
 Eicosenoic acidf 2.36 8.56E-08 3.03E-03 1.96 
 3-Hydroxybutyratee 2.21 5.33E-05 1.27E-02 2.61 
Carbohydrates metabolism Pyruvatee 2.46 1.24E-05 1.03E-02 1.88 
 Lactatee 1.94 2.71E-03 2.18E-02 1.24 
 Citratee 2.34 7.46E-06 7.88E-03 1.45 
 2-Oxoglutaratee 2.57 1.82E-06 5.45E-03 1.59 
 Malatee 3.07 2.21E-08 1.82E-03 1.57 
Amino-acid metabolism Glutamatee 2.35 4.26E-05 1.21E-02 1.63 
 Aspartatee 2.60 3.44E-06 7.27E-03 1.38 
 5-Oxoprolinef 2.52 3.68E-07 3.64E-03 1.35 
 Serinee 1.69 7.07E03 2.48E-02 1.13 
 Phenylalaninee 1.96 4.26E-04 1.88E-02 1.14 
 Cystinee 2.99 1.06E06 4.24E-03 -1.36 
 2-Aminobutyratee 1.71 2.44E-02 3.45E-02 1.28 
 2-Hydroxybutyratee 2.91 7.99E-08 2.42E-03 2.45 
Inositol phosphate metabolism myo-Inositole 1.57 2.42E-02 3.39E-02 1.16 
Abbreviations: FDR, false discovery rate; GC-TOF, gas chromatograph time of flight; OPLS, orthogonal projection to latent structures; SZ-BL, 
schizophrenia patients at baseline. 
 For metabolites from serum analyzed by GC-TOF. 
a VIP shows variable importance in the projection obtained from the OPLS model with a cutoff of 1.5. 
b P-values from non-parametric Wilcoxon–Mann–Whitney test. 
c FDR was calculated with a q-value of 0.2. Paired t-test was used to investigate the difference between SZ-BL and SZ-4w. 
d FC is a positive value fold change that indicates a relatively higher concentration present in SZ-BL (SZ-4w), while a negative value means a 
relatively lower concentration as compared to the controls (SZ-BL). 
e Metabolites were verified by reference compounds. 
f Metabolites were identified using available library databases. 
 
 
Figure 2: 
 
Composite biomarker panel for schizophrenia. (a) Scores plot of orthogonal projection to latent structures (OPLS) discriminating urine profiles of 
schizophrenia patients at baseline (SZ-BL) and normal controls. (b) In all, 21 metabolites identified from the OPLS model with variable 
importance on a projection (VIP) >1.5. (c) Logistic regression models fitted with different numbers of metabolites. The smallest Akaike 
information criterion (AIC) was of the model with the five serum metabolites (glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and 
cystine), the same as those in serum biomarker panel. The logistic regression with the addition of urine β-hydroxybutyrate to the serum panel had 
a similar AIC value to perfectly predict classification of schizophrenia or control. Thus, the urine β-hydroxybutyrate and the serum biomarker 
consisted a so-called ‘composite biomarker panel for schizophrenia’. (d) ROC curves of the composite biomarker panel in the training and test 
sets. 
 
Table 3: Differential urine metabolites in schizophrenia patients. 
Pathway Compound VIPa P-valueb FDRc FCd 
Fatty acids metabolism Suberic acide 2.05 1.44E-04 3.74E-03 1.59 
 3-Hydroxysebacic acide 1.59 3.53E05 1.87E03 5.55 
 3-Hydroxyadipic acide 2.35 3.34E04 4.36E-03 2.06 
 2-Ethyl-3-hydroxypropionic acide 1.53 5.65E02 5.30E-02 1.29 
 4-Pentenoic acide 2.14 6.07E-03 2.18E-02 1.54 
 Threonic acidf 1.64 5.82E02 5.36E02 1.21 
 2,3-Dihydroxybutanoic acide 1.58 6.19E-03 2.24E-02 -1.3 
 2-Hydroxybutyric acidf 1.55 3.23E-03 1.81E-02 1.41 
 3-Hydroxybutyric acidf 1.6 5.83E-03 2.06E-02 1.37 
 Hydroxyacetic acidf 2.09 1.90E-03 1.56E-02 -1.36 
Carbohydrates metabolism cis-Aconitic acidf 1.99 1.23E-02 3.30E-02 1.28 
Amino-acid metabolism Cystinef 1.55 1.20E-03 9.97E-03 1.54 
 Valinef 1.72 3.56E-02 4.42E-02 1.07 
 Isoleucinef 1.94 1.26E-03 1.06E-02 1.3 
 Glutamatef 1.68 6.85E-03 2.43E-02 1.35 
 Pyroglutamic acidf 1.83 2.60E-03 1.62E02 1.25 
 Catechole 1.77 5.82E04 7.48E-03 -1.83 
 Pipecolinic acidf 1.76 1.51E-03 1.31E-02 1.65 
 2-Aminoadipic acide 1.51 6.58E-03 2.37E-02 -1.27 
 2-Aminobutyric acidf 1.89 1.19E-02 3.12E-02 1.45 
 Glycocyaminee 1.96 6.74E-04 8.10E-03 -1.89 
Abbreviations: FDR, false discovery rate; GC-TOF, gas chromatograph time of flight; OPLS, orthogonal projection to latent structures; SZ-BL, 
schizophrenia patients at baseline. 
 For metabolites from urine analyzed by GC-TOF. 
a VIP shows variable importance in the projection obtained from the OPLS model with a cutoff of 1.5. 
b P-values from non-parametric Wilcoxon–Mann–Whitney test. 
c FDR was calculated with a q-value of 0.2. 
d FC is a positive value fold change that indicates a relatively higher concentration present in SZ-BL, while a negative value means a relatively 
lower concentration as compared to the controls. 
e Metabolites were identified using available library databases. 
f Metabolites were verified by reference compounds. 
 
 
We also employed the 1H-NMR platform to analyze the urine samples from 41 schizophrenia 
patients and their matched controls in the training set. Glucose was found elevated in SZ-BL by 
both analytical platforms (Table 4), although not significantly different between SZ-BL and 
controls in GC-TOFMS data. Chemical shift of 3-hydroxybutyrate was found increased in urine 
of schizophrenia patients, which is in accordance with the GC-TOFMS results. Other ketone 
bodies, acetone and acetoacetate, which were not detected by GC-TOFMS, were found elevated 
by NMR. 
 
Biomarker panel for diagnosis of schizophrenia 
In the serum training set (Table 1), the sensitivity and specificity of the OPLS classifier model 
reached 95.2% and 98.4%, respectively (Supplementary Figure 2). The prediction package in the 
SIMCA-P software was applied to predict the test set with the OPLS model. The supervised 
variable Y of controls was designated 1 and that of schizophrenia patients 2. The Y-predicted 
scatter plot assigned samples to either the control or the schizophrenic group using an a priori 
cutoff of 1.5, that is, individuals with YPred (Y predicted) >1.5 were considered as schizophrenic 
patients and those with <1.5 as normal. A total of 41 out of 50 patients in the test set were 
correctly classified, reaching a satisfactory sensitivity of 82.0% and specificity of 89.6% 
(Supplementary Figure 2). These results suggest that this OPLS model constructed by the serum 
metabolites provides great potential for molecular diagnosis of schizophrenia. 
 
Table 4: Metabolites identified by 1H-NMR and GC-TOFMS. 
Metabolite NMR  GC-TOFMS 
 Shift P-valuea FCb  P-value FC 
Glucose 3.46 1.73E-04 1.79  2.87E-01 1.14 
Citrate 2.66 5.58E-03 -1.34  2.75E-01 -1.19 
Lactate 4.10 2.09E-08 -1.30  7.58E-03 1.48 
Acetone 2.22 1.90E-03 1.74  Not found 
Acetoacetate 2.26 5.96E-02 1.23  Not found 
3-Hydroxybutyrate 1.22 6.47E-01 1.58  5.83E-03 1.37 
Abbreviations: GC-TOFMS, gas chromatograph time-of-flight mass spectrometer; NMR, nuclear magnetic resonance; SZ-BL, schizophrenia 
patients at baseline. 
a P-values from non-parametric Wilcoxon–Mann–Whitney test. 
b FC is a positive value fold change that indicates a relatively higher concentration present in SZ-BL, while a negative value means a relatively 
lower concentration as compared to the controls. 
 
 
ROC analysis is a classical methodology from signal detection theory and is now commonly 
used in clinical research.38 Diagnosis based on quantification of fewer metabolites will be more 
convenient and economical if they can provide sufficient information. To explore a simplified set 
of schizophrenia biomarkers, metabolites in the serum with higher fold change and VIP value 
were used as candidates (Table 2 and Figure 1b), although the pre-selecting marker candidates 
may result in positively biased cross-validation estimates. We calculated the AUC for each 
candidate as a classifier and sorted the AUC in descending order. Logistic regression was then 
fitted from first 2 to 8 variables (Figure 1c). According to the Akaike information criterion 
(AIC), the logistic regression with five variables explained most deviations between SZ-BL and 
normal controls using the smallest numbers of variables. In particular, the models with 6–8 
variables disclosed that the five-variable model had the highest predictive power when we 
performed a stepwise, backward-elimination mode. These five metabolites were glycerate, 
eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine. ROC curves of the serum panel for the 
training and test set were drawn with the odds ratio (Figure 1d). The AUC of this biomarker 
panel was 0.945 (95% confidence interval: 0.900–0.991) in the training set and 0.895 (95% 
confidence interval: 0.829–0.961) in the test set. According to the traditional academic points 
system, an area of 1 represents a perfect test, while an area of 0.5 represents a worthless test. 
Thus, we obtained a ‘good’ classifier of schizophrenia patients and normal controls. 
 
The differential metabolites in urine, which reflected early changes in disease, could also 
supplement the serum metabolite markers. We calculated the AUCs of logistic regression models 
composed of the five metabolites in the serum panel added by each metabolite in Table 3. Most 
of the newly constructed panels have increased AUCs than the original serum panel 
(Supplementary Table 1). Of note, the composite panel by addition of a urinary metabolite, 3-
hydroxybutyrate, to the serum panel achieved an AUC of 1.00 in both the training set and test 
set, meaning an equivalent diagnosis compared with the clinical interviews (Figure 2d). 
 
Similar metabolic profile of first-episode and recurrent schizophrenia patients 
Among the 112 schizophrenia patients, 64 were diagnosed on first episode and the others were 
recurrent. Serum metabolic profile of the first episode was found similar to that of the recurrent, 
as multivariable partial least squares-discrimination analysis or OPLS models were not 
constructed with reliable model parameters, indicating that the serum metabolic profile of the 
first-episode subjects is not distinct from that of the recurrent subjects. Metabolites were either 
with P-values >0.05 from Wilcoxon–Mann–Whitney test or screened out by FDR correction 
with q set at 0.2 in both the serum and urine data. As a result, the similar metabolic profiles of 
first-episode and recurrent patients were not able to generate identifiable metabolite markers to 
differentiate first-episode patients from those with recurrent disease. 
 
DISCUSSION 
Potential diagnostic panel for schizophrenia 
A series of research in genetics, proteomics as well as imaging have been designated to the 
discovery of markers in schizophrenia. However, it is still a challenge to gain a marker that could 
replace or even aid diagnosis of this severe disease. In this study, we acquired GC-TOFMS 
spectra of serum and urine metabolites from 112 schizophrenia patients and 110 healthy subjects. 
Within the identified differential metabolites, a serum biomarker panel consisting of five 
metabolites (glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine) was 
established using logistic regression. This biomarker panel is a ‘good’ classifier for diagnosing 
schizophrenia in that AUC achieved 0.945 in the training set and 0.895 in the test set. In 
particular, the fact that patients and controls in the test set were not matched in gender and age 
suggested an unbiased discrimination of this set of biomarkers in the general population. In 
addition, supplement of urine 3-hydroxybutyrate to the serum panel offers an equivalent 
diagnosis to the clinical interviews, with AUC achieving 1 in both training and test set. Further, 
insights for schizophrenia mechanism could be obtained from pathways behind these biomarkers. 
 
Metabolic evidences for energy metabolism disorder 
Pyruvate is an important intermediate in glucose metabolism, connecting glycolysis and the 
tricarboxylic acid cycle. In adults, the brain accounts for 20% of the total body basal oxygen 
consumption and 25% of the total body glucose utilization, although constituting only 2% of 
body weight.39 Glycolysis coupled with the tricarboxylic acid cycle fully oxidizes glucose and 
supplies energy for the brain. An increased supply of glucose in the blood has been found to 
enable better memory performance in schizophrenic patients.40 Converging evidence41, 42, 43, 44 
suggests that malfunction of glucose metabolism may be a causative factor for schizophrenia. A 
higher prevalence of glucose tolerance and insulin resistance in patients with first-onset 
schizophrenia has been attributed to abnormal glucose metabolism.45, 46, 47 An increased level of 
pyruvate observed in this study indicates increased energy production and demand in 
schizophrenic subjects. A higher energy demand has been found to result from inefficiency in 
brain circuitry.48 
 
Glycerate, eicosenoic acid and β-hydroxybutyrate are the metabolites produced from the 
degradation of glyceride and fatty acids. Owing to the elevated levels of glycerate, eicosenoic 
acid indicates an increased fatty acid catabolism as an alternative energy source in schizophrenia 
subjects. Especially, concentration of eicosenoic acid was significantly increased in the 
pretreatment of schizophrenic patients (P=8.56E-08, fold change=1.96), which has also been 
reported as being elevated in the red blood cells of children suffering from autism as compared 
with typically developing controls.49 
 
The brain requires continuous delivery of substrate by the blood to support energy consumption. 
Ketone bodies can and do in some naturally occurring conditions substitute, at least in part, for 
glucose.39 Ketone bodies are produced primarily in the liver as a by-product of fatty acid 
mobilization. As the liver increases its rate of production of ketone bodies in association with 
increased fatty acid metabolism, it releases them into the blood for utilization by other tissues. 
This elevated serum fatty acids and β-hydroxybutyrate is presumed to be as a result of high level 
of glyceride mobilization in response to higher energy demand in the brain, which is supported 
by the accumulation of short- to middle-chain fatty acids and ketone bodies in urine (Figure 3). 
A long-term shortage of energy from glucose metabolism may push the brain to change the 
expression of genes related to fatty acid metabolism, resulting in higher concentration of 
transcripts in post-mortem brain tissue.24 
 
Figure 3: 
 
Disordered energy metabolism in schizophrenia. The brain uses glucose in circulation as its main energy source, 
with ketone bodies as an alternative. In schizophrenic patients, brain energy supply is scarce owing to mitochondrial 
dysfunction. Hence, the brain is presumed to have to partially shift its energy supply towards ketone bodies, and 
fatty acid metabolism in the liver is then mobilized to produce the necessary ketone bodies. 
 
Pathways related to energy metabolism have been found to be associated with schizophrenia 
based on evidence from proteins, transcripts and metabolites in the human brain.23, 24 Based on 
the serum and urine metabolite changes we observed, we hypothesized that systematic 
alternations on glycogenolysis and lipid metabolism occurred in the schizophrenia patients 
(Figure 3). Fatty acid mobilization, resulting from intrinsic inhibited glucose metabolism in the 
brain, accounts for the increase of free fatty acids in the serum and ketone bodies in the urine of 
schizophrenic patients. The increased consumption of ketone bodies also suggests that a shortage 
in glucose utilization may push the brain to shift part of its energy supply from glucose towards 
ketone bodies in schizophrenic patients. If the disease progresses, the brain cells have to increase 
the transcription of fatty acid metabolism, as evidenced by decreased glycolysis and increased 
glycogen and fatty acid catabolism transcripts reported in the post-mortem brain.24 
 
In our study, free fatty acids such as tetradecanoic acid, hexadecanoic acid and octadecanoic acid 
were found significantly elevated in the serum of schizophrenia patients at baseline, which is not 
consistent with previously reported plasma lipids.30 This might be due to the different classes of 
compounds (free fatty acids vs lipids) detected with the respective platforms. For example, GC-
TOFMS can readily capture small-molecule fatty acids, but is not amenable to detecting 
phospholipids. 
 
Cystine (cysteine) in antioxidant defense system 
Reactive oxygen species (ROS) resulting from oxidative phosphorylation and metabolic 
transformations cause oxidative damage in cellular DNA, RNA, proteins as well as lipids 
constructing various membranes.50 The antioxidant glutathione (GSH; L-γ-glutamyl-L-cysteinyl-
glycine) is essential for the cellular detoxification of ROS in brain cells.51 Cystine is the 
preferred form of cysteine for the synthesis of GSH in cells involved in the immune function, 
including macrophages and astrocytes (http://www.hmdb.ca). Cystine, as the oxidized form of 
cysteine in the extracellular space (serum), is a rate-limiting substrate for GSH synthesis. 
Maintenance of intracellular GSH drives cystine transport across plasma membrane under 
oxidative stress.52 The depletion of serum cystine observed in this study may be indicative of a 
compromised GSH system in the brain under increased oxidative stress in neurological diseases. 
This observation is supported by the higher concentration levels of 2-hydroxybutyrate (and its 
amino derivative, 2-aminobutyrate) in the serum of the schizophrenia patients, which is a by-
product of the reaction-producing cysteine from homocysteine. These results are consistent with 
a previous study in which transcripts related to GSH synthesis were found to be increased in 
human brain tissues.24 In addition, 2-hydroxybutyrate has been found to be an early biomarker 
for insulin resistance and glucose intolerance in a non-diabetic population, indicating that it also 
has a close association with energy metabolism.53 
 
The elevation of cystine in the serum and depletion in the urine is presumably due to the 
different metabolic/excretion rates in different biological compartments. 
 
Glutamate as neurotransmitter and/or energy source 
Glutamate is the predominant excitatory neurotransmitter of the vertebrate central nervous 
system.54 It plays a critical role in synaptic maintenance and plasticity,55 and also involves in 
learning and memory. Under normal conditions, brain glutamate concentration is highly 
regulated at both sides of the brain–blood barrier. As a result, the fluctuation of glutamate 
concentration in circulation brings little influence to glutamate in the brain. However, the 
alteration of serum glutamate level is of neurological importance as it is closely associated with 
the metabolism of γ-aminobutyric acid, the primary inhibitory neurotransmitter. 
 
The elevated concentration of glutamate in the serum is presumably indicative of insufficient 
energy supply in the brain under schizophrenia, as glutamate also serves as an important fuel 
reserve. When insufficient glucose concentration or glycolytic flux occurs in the brain, glutamate 
is mobilized as alternative fuel to glucose.56 
 
CONCLUSION 
We used the GC-TOFMS and NMR analytical platforms to characterize the metabolic profiles of 
serum and urine from schizophrenic patients. A biomarker panel composing of five serum 
metabolites (glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine) was 
established to discriminate schizophrenic patients from normal controls. A composite panel by 
the addition of urine β-hydroxybutyrate to the serum panel achieved AUC of 1 in both the 
training set and test set, meaning an equivalent diagnosis to clinical interviews. Elevated fatty 
acids and ketone bodies were found in both the serum and urine of patients, suggesting an 
upregulated fatty acid catabolism, presumably resulting from an insufficiency of glucose supply 
in the brains of schizophrenia patients. In addition, metabolic profile of schizophrenia patients on 
first episode was found similar to that of recurrent ones when we compared the metabolites in the 
serum and urine from the two groups. 
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